Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fecal Immunochemical Test Assessed in Suspected Colorectal Cancer

By LabMedica International staff writers
Posted on 05 Nov 2020
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue.

The fecal immunochemical test (FIT) detects the globin component of hemoglobin (Hb) by immunoassay and can reliably measure the fecal Hb concentration (f-Hb) to the nearest microgram of Hb per gram of faces (µg/g). Since 2010, over 25 diagnostic accuracy studies have reported data on the use of FIT in symptomatic patients utilizing a range of cut-offs.

A team of medical scientists led by those at Croydon University Hospital (Croydon, UK) analyzed almost 10,000 patients referred to a specialist for suspected CRC symptoms that met criteria for urgent care. FIT sensitivity was maximized to 97.0% at the lowest fecal hemoglobin concentration cutoff of 2 µg/g. Between October 2017 and December 2019, 21,126 patients were sent recruitment packs, 13,219 (62.6%) returned FIT devices. Complete FIT and colonoscopy outcomes were available for 9,822 patients, who were included in the study results. Median age was 65 in the final cohort of kit-returning patients, 54% of whom were women.

FIT analysis was performed at one centralized laboratory where staff were blinded to patient clinical information. The HM-JACKarc analytical system (Hitachi Chemical Diagnostics Systems, Tokyo, Japan) was used to analyze all samples. The analytical working range is 7–400 µg/g. The limit of detection (LoD) of the assay is 2 µg/g and the limit of quantitation is 7 µg/g. The National Institute for Health and Care Excellence (NICE) recommended an f-Hb cut-off of 10 µg/g in the DG30 guidelines. Colonoscopy was chosen as the reference standard since it is acknowledged to be the gold-standard investigation for colorectal disease. Colonoscopists were blinded to the FIT results.

The team reported that incidence of CRC at colonoscopy was 3.3%. At fecal hemoglobin concentration cutoffs of 2, 10, and 150 µg/g, FIT positivity decreased from 37.2% to 19.0% and 7.6%, respectively. The positive predictive values of FIT for CRC was 8.7% at the 2 µg/g cutoff, 16.1% at the 10 µg/g cutoff, and 31.1% at the 150 µg/g cutoff. Respective negative predictive values were 99.8%, 99.6%, and 98.9%. In terms of sensitivity for CRC, this decreased from 97.0% at the 2 µg/g cutoff, to 90.9% at the 10 µg/g cutoff, and 70.8% at the 150 µg/g cutoff. Specificity increased from 64.9% to 83.5% and 94.6%, respectively.

The authors concluded that a higher hemoglobin cutoff could be set to match capacity in resource-limited settings, which would reduce the number of positive results, onwards referral for investigation and demand for colonoscopy but at the expense of detecting fewer cancers. The study was published on October 21. 2020 in the journal GUT.

Related Links:
Croydon University Hospital
Hitachi Chemical Diagnostics Systems



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.